Drug Trial Radar · NCT07935291
Study of IPG1094 Tablets in Chinese Healthy Adults and Obese Adults
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Nov 25, 2026
Primary completion
Jun 25, 2027
Study completion Aug 25, 2027
Sponsor
- Lead sponsor
- Nanjing Immunophage Biotech Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Zhejiang Hospital
- First posted
- Nov 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary weight-loss effect of IPG1094 tablets. The study includes three parts: Part A is single ascending dose in healthy volunteers; Part B is multiple ascending dose in healthy volunteers; Part C is multiple-dose exploration in obese adult participants. Subjects will be randomly assigned to receive IPG1094 or matching placebo. Safety, blood drug concentration and weight-related indicators will be followed up.
Conditions
- Healthy Volunteers; Obesity
Interventions
IPG1094 Tablet and matching PlaceboDrug
IPG1094 tablet is a macrophage migration inhibitory factor(MIF) modulator tablet; matching placebo identical in appearance, dosage form and number of tablets. Part A: single oral dose under fasting condition. Part B: multiple oral doses after standard meal; B1-B3 QD ×10 d; optional B4: BID ×9 d, morning dose only on Day10. Part C: obese participants take drug after standard breakfast; C1/C2 28-day QD; C3 90-day QD; D-1-D10 in-hospital; subsequent home administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Maximum Observed Plasma Concentration (Cmax) of IPG1094 after single doseTime frame: Up to 96 hours post-dose
- Part A: Time to Maximum Plasma Concentration (Tmax) of IPG1094 after single doseTime frame: Up to 96 hours post-dose
- Part A: Terminal Elimination Half-life (t1/2) of IPG1094 after single doseTime frame: Up to 96 hours post-dose
- Part A: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of IPG1094 in Part ATime frame: Up to 96 hours post-dose
- Part A: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of IPG1094 in Part ATime frame: Up to 96 hours post-dose
- Part A: Apparent Oral Clearance (CL/F) of IPG1094 in Part ATime frame: Up to 96 hours post-dose
- Steady-State Maximum Observed Plasma Concentration (Css,max) of IPG1094 in Part BTime frame: Day 1 to Day 13
- Time to Steady-State Maximum Plasma Concentration (Tss,max) of IPG1094 in Part BTime frame: Day 1 to Day 13
- Area Under the Plasma Concentration-Time Curve Over One Dosing Interval at Steady State (AUC0-τ) of IPG1094 in Part BTime frame: Day 1 to Day 13
- Steady-State Apparent Oral Clearance (CLss/F) of IPG1094 in Part BTime frame: Day 1 to Day 13
- Accumulation Index Based on AUC (Rac,AUC) of IPG1094 in Part BTime frame: Day 1 to Day 13
- Accumulation Index Based on Cmax (Rac,Cmax) of IPG1094 in Part BTime frame: Day 1 to Day 13
- Safety indicators:adverse eventTime frame: Day30 for 100/200 mg QD groups;Day90 for 300 mg QD group
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhejiang Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.